Actively Recruiting

Phase Not Applicable
Age: 40Years - 75Years
All Genders
NCT06239974

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Led by The University of Hong Kong · Updated on 2025-10-07

94

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.

CONDITIONS

Official Title

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Who Can Participate

Age: 40Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Stable recurrent chest pain
  • Age between 40 and 75 years
  • Coronary CT angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (less than 50% stenosis or fractional flow reserve above 0.8)
  • Stress CMR myocardial perfusion reserve less than 2.19 or stress myocardial blood flow less than 2.19 ml/g/min
  • Female participants must not be pregnant or breastfeeding, or if women of childbearing potential, agree to follow contraceptive guidance during and for at least 1 month after the study intervention
Not Eligible

You will not qualify if you...

  • Systolic blood pressure below 100 mm Hg
  • Current use of soluble guanylate cyclase stimulators or phosphodiesterase type 5 inhibitors
  • Known allergy or sensitivity to soluble guanylate cyclase stimulators
  • Use of long-acting nitrates
  • Known cardiomyopathy, complex congenital heart disease, endocarditis, or pericarditis
  • Acute coronary syndrome or coronary revascularization within 60 days prior to randomisation, or indication for revascularization at randomisation
  • Symptomatic carotid stenosis, transient ischemic attack, or stroke within 60 days prior to randomisation
  • Estimated glomerular filtration rate below 30 mL/min/1.73m2
  • Malignancy or other non-cardiac condition limiting life expectancy to less than 3 years
  • Implanted devices not compatible with MRI

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The University of Hong Kong

Hong Kong, Hong Kong

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM) | DecenTrialz